Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review
- PMID: 35499517
- PMCID: PMC9897643
- DOI: 10.1080/21645515.2022.2062983
Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review
Abstract
There is a wealth of data suggesting that the effectiveness of existing vaccines against the Omicron variant, the most mutated SARS-CoV-2 variant to date, has been substantially reduced if only primary vaccination is administered. Therefore, the effectiveness of booster vaccination against the Omicron variant has become a topic of current interest. We conducted a comprehensive search in PubMed, Embase, and the Cochrane Library to collect various pseudovirus neutralization tests or live virus neutralization tests for the Omicron variant, with serum specimens from booster vaccinees. We extracted neutralization titers for the Omicron variant, the original strain, and the other variants before and after booster vaccination, and then manually calculated the fold increase or decrease in neutralization titers for the Omicron variant relative to the other variants, and the fold increase in neutralization titers for the Omicron variant after booster vaccination compared with that before booster vaccination. In the two-dose vaccination regimen, the neutralization titers against the Omicron variant decreased substantially compared to the original strain and other variants. However, after booster vaccination, both homologous and heterologous booster vaccination, the neutralization of serum antibodies against the Omicron variant was significantly improved, although still lower than that of the original strain and other variants. The booster vaccination program based on existing vaccines can produce broad but incomplete immunity against the Omicron variant.
Keywords: COVID-19; SARS-CoV-2; public health; the Omicron variant; vaccines.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures
Similar articles
-
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.J Clin Oncol. 2022 Nov 20;40(33):3808-3816. doi: 10.1200/JCO.21.02986. Epub 2022 Jun 27. J Clin Oncol. 2022. PMID: 35759727 Free PMC article.
-
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633. Elife. 2022. PMID: 36004719 Free PMC article.
-
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.Emerg Microbes Infect. 2022 Dec;11(1):337-343. doi: 10.1080/22221751.2021.2022440. Emerg Microbes Infect. 2022. PMID: 34935594 Free PMC article.
-
Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.Front Immunol. 2022 Aug 24;13:940562. doi: 10.3389/fimmu.2022.940562. eCollection 2022. Front Immunol. 2022. PMID: 36091023 Free PMC article.
-
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.Front Public Health. 2022 Jul 13;10:940956. doi: 10.3389/fpubh.2022.940956. eCollection 2022. Front Public Health. 2022. PMID: 35910897 Free PMC article.
Cited by
-
Case Report: The Experience of Managing a Moderate ARDS Caused by SARS-CoV-2 Omicron BA.2 Variant in Chongqing, China: Can We Do Better?Front Med (Lausanne). 2022 Jun 9;9:921135. doi: 10.3389/fmed.2022.921135. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35755038 Free PMC article.
-
Evaluation of the Efficacy of COVID-19 Booster Vaccinations in Healthcare Personnel.Vaccines (Basel). 2022 Oct 26;10(11):1797. doi: 10.3390/vaccines10111797. Vaccines (Basel). 2022. PMID: 36366305 Free PMC article.
-
The Scabbard of Excalibur: An Allegory on the Role of an Efficient and Effective Healthcare System under Universal Health Coverage during the Pandemic Response.Healthcare (Basel). 2024 May 9;12(10):979. doi: 10.3390/healthcare12100979. Healthcare (Basel). 2024. PMID: 38786389 Free PMC article.
-
COVID-19-Related Burnout and Intention of Fully Vaccinated Individuals to Get a Booster Dose: The Mediating Role of Resilience.Vaccines (Basel). 2022 Dec 27;11(1):62. doi: 10.3390/vaccines11010062. Vaccines (Basel). 2022. PMID: 36679907 Free PMC article.
-
Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths.J Pers Med. 2022 Jun 18;12(6):995. doi: 10.3390/jpm12060995. J Pers Med. 2022. PMID: 35743779 Free PMC article. Review.
References
-
- Genovese L, Zaccaria M, Farzan M, Johnson W, Momeni B.. Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via ab initio quantum mechanical modeling. BioRxiv. 2021. doi: 10.1101/2021.12.01.470748. - DOI
-
- Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoako D, et al. SARS-CoV-2 omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. MedRxiv. 2021. doi: 10.1101/2021.12.08.21267417. - DOI
-
- Pfizer . Pfizer and biontech provide update on omicron variant. The United States; 2021. Dec 8 [accessed 2021 Dec 20]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-an....
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous